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Background: One out of ten newly diagnosed patients in Europe was infected with a virus carrying a drug
resistant mutation. We analysed the patterns over time for transmitted drug resistance mutations (TDRM) using data
from the European Spread program.
Methods: Clinical, epidemiological and virological data from 4317 patients newly diagnosed with HIV-1 infection
between 2002 and 2007 were analysed. Patients were enrolled using a pre-defined sampling strategy.
Results: The overall prevalence of TDRM in this period was 8.9% (95% CI: 8.1-9.8). Interestingly, significant changes
over time in TDRM caused by the different drug classes were found. Whereas nucleoside resistance mutations
remained constant at 5%, a significant decline in protease inhibitors resistance mutations was observed, from 3.9%
in 2002 to 1.6% in 2007 (p = 0.001). In contrast, resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs)
doubled from 2.0% in 2002 to 4.1% in 2007 (p = 0.004) with 58% of viral strains carrying a K103N mutation.
Phylogenetic analysis showed that these temporal changes could not be explained by large clusters of TDRM.
Conclusion: During the years 2002 to 2007 transmitted resistance to NNRTI has doubled to 4% in Europe. The
frequent use of NNRTI in first-line regimens and the clinical impact of NNRTI mutations warrants continued
monitoring.
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The use of combination antiretroviral therapy has strongly
reduced morbidity and mortality among patients infected
with HIV [1]. This use of antiretroviral medication has,
however, also led to transmission of drug resistant HIV-1.
Approximately 10-15% of antiretroviral naïve patients in
Europe [2-5] and North-America [6,7] were infected with
a virus carrying at least one transmitted drug resistance
associated mutation (TDRM). These individuals are at a
higher risk for developing virological failure to first-line
antiretroviral therapy [8].
The objective of this study is to determine the trends in
transmitted drug resistance in newly diagnosed HIV-1
infected patients over time in Europe. For this purpose,
we analyzed the data collected by the pan-European
SPREAD programme. This programme combines the ef-
forts of virologists, clinicians and public health institutes
to study the epidemiology of transmission of drug re-
sistant HIV [2,9]. SPREAD has used since 2002 the same
sampling strategies for inclusion of patients newly diag-
nosed with HIV-1.
Methods
Ethics statement
Ethical requirements are fulfilled according to the proce-
dure described in the EC contract. The procedure differs
among the 32 countries in the network according to
national legislation. Briefly, for each participating hospital
or collection center, approval was obtained by the insti-
tutional medical ethical review committee. Additionally, a
written informed consent was obtained for each patient.
In countries where a mandatory surveillance system was
already established, legally no informed consent was
needed. All surveillance data were made anonymous and
coded at national level.
Study population
The SPREAD Program includes patients with newly di-
agnosed HIV-1 infection from September 2002 through
December 2007 in 26 European countries (Austria, Belgium,
Bulgaria, Croatia, Cyprus, Czech Republic, Denmark,
Germany, Finland, Greece, Ireland, Italy, Latvia, Lithuania,
Luxembourg, the Netherlands, Norway, Poland, Portugal,
Romania, Serbia, Slovakia, Slovenia, Spain, and Sweden)
and Israel. Although Israel is not officially part of Europe,
the WHO includes Israel in the WHO European region
definition [10]. Patients were included using a pre-defined
sampling strategy based on the geographical and risk
group distribution of patients newly diagnosed with HIV
in the participating countries. For more details on the
sampling strategy, inclusion- and exclusion criteria, and
ethical clearance see the previous publications from the
SPREAD Programme [2,9]. Epidemiological, clinical,
and behavioral data were collected using a standardizedquestionnaire within six months of diagnosis. A tho-
rough data verification process preceded the analysis of
the data [2,9].
A blood sample was taken for genotypic resistance test-
ing within six months after diagnosis. Population-based
nucleotide sequencing of parts of the reverse transcriptase
(RT) and protease (PR) genes of the virus was performed
at local laboratories by means of commercially available
kits or in-house methods [2,9]. All countries took part in a
blinded quality control program to verify the quality of the
genotypic data generated. TDRM was defined according
to the mutation list published for surveillance of transmit-
ted drug resistance as recommended by the World Health
Organization [11].
Seroconversion was documented in a proportion of the
newly diagnosed patients. For some of these patients
(n = 882) seroconversion could be established because a
last negative test was available within 3 years before diag-
nosis. In these patients, the date of infection was estimated
as the midpoint between the date of the last negative and
first positive test. In addition, for 506 patients primary
HIV-1 infection was documented based on laboratory
data (i.e. they had documented negative or indeterminate
HIV-1 serological results up to 12 months prior to con-
firmation of diagnosis by western blot). In these 506 pa-
tients, the date of the first positive (and subsequently
confirmed) HIV test was used as the estimated date of in-
fection. Patients were defined as recently infected when
the duration of infection was <1 year [12].
For the purpose of analysis, Western Europe was
defined to include those countries with a long history of
good access to antiretroviral drugs. These countries in-
cluded: Austria, Belgium, Cyprus, Germany, Denmark,
Spain, Finland, Greece, Ireland, Italy, Luxembourg, the
Netherlands, Norway, Portugal, Sweden, France, the
United Kingdom, Switzerland, and Iceland. In our study,
Israel was also included in the Western Europe category.
The HIV-1 subtypes were determined by use of the Rega
HIV-1 subtyping tool (version 2.0, available at http://www.
bioafrica.net/rega-genotype/html/) [13].
Phylogenetic analyses
Phylogenetic analyses were performed to investigate
clustering of sequences with TDRM. As controls we in-
cluded 1) the genetically most closely related sequences
in the entire SPREAD dataset (n = 46) as identified by
neighbor-joining phylogenetic trees constructed using
Mega5; 2) the most closely related sequences (according
to the percent of matching bases) in the Los Alamos
Sequence Database (www.hiv.lanl.gov) as identified using
the HIV BLAST tool (n = 55; 3) subtype reference from
the Los Alamos Sequence Database.
Sequences were aligned using Clustal W (BioEdit version
7.0.5.3) software followed by manual editing and removal
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were constructed for each relevant subtype using Mega5
and the best fitting nucleotide substitution model estimated
by ModelTest v0.1.1 [14] under the Akaike information cri-
terion. Robustness and statistical support of the internal
branches of the maximum likelihood tree were evaluated
with bootstrap analysis (1000 replicates). Potential non-
nucleoside reverse transcriptase inhibitors (NNRTI) trans-
mission clusters were defined as cluster including only
sequences with at least one NNRTI TDRM with >70%
bootstrap support and a mean genetic distance of <0.03 nu-
cleotide substitutions per site [15,16].
Statistical analyses
The data were analysed using the statistical software R
(version 2.11.1). Categorical data were compared by use
of the χ2 test, Fisher exact test, or logistic regression
techniques. Continuous data were investigated by means
of the Mann–Whitney U test, linear regression, or Pois-
son regression. Prevalence values were calculated with a
95% Wilson score confidence interval (CI) on the basis
of a binomial distribution. Trends in the prevalence of
TDRM were calculated by logistic regression. SeveralTable 1 Characteristics of all included HIV-1 patients and pat
drug resistance mutations to NRTI, NNRTI, or PI drug class
Characteristics Categories Total
Patients 4317
Continent of origin, no (%) Western Europe 2404 (56)
Eastern Europe & Central Asia 919 (21)
Sub-Saharan Africa 472 (11)
Other 354 (8)
Unknown 168 (4)
Gender, no. (%) Male 3411 (79)
Risk group, no. (%) MSM 2084 (48)
Hetero 1501 (35)
Injecting drug use 355 (8)
Unknown 377 (9)
Subtype, no. (%) B 2855 (66)
non-B 1381 (32)
Unknown 81 (2)
Duration of infection, no (%) <1 year 1236 (29)
1-2 years 144 (3)
Unknown 2937 (68)
Plasma HIV-RNA, median (IQR), log copies/ml 4.9 (4.3-5.3
CD4 cell count, median (IQR), cells/mm3 352 (180–
Age, median years (IQR) 35 (29–42
NOTE. NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside rever
men; IQR, interquartile ranges; aTDRM’s from multiple classes was found in 49 (22.5
respectively, and are therefore counted in more than one drug resistance column. M
for NRTI-PI in 27 patients and NNRTI-PI in 17 patients. Resistance for all three drugfactors were investigated as potential risk factors for
TDRM: route of infection, recent infection, subtype, sex,
age, continent of origin, CDC stage, CD4 cell count
(square root transformed), log viral load. All statistically
significant (P < 0.1) univariate predictors of TDRM were
considered as possible confounding factors in the multi-
variate time trend analysis.
Results
Population characteristics
The SPREAD programme enrolled 4,470 newly diag-
nosed HIV-1 patients from September 2002 through
December 2007. Included here are 4,317 patients for
whom genotypic information was available. Data from pa-
tients included until 2005 (n = 2687) have been reported
previously [2,9]. The current analysis contains 1630 ad-
ditional patients, included between January 2006 and
December 2007.
Table 1 shows the baseline characteristics for all pa-
tients. More than half (56%) originated from Western
Europe, followed by patients originating from Eastern
Europe and Central Asia (21%) and from Sub-Saharan
Africa (11%). The most commonly reported transmissionients carrying a wild-type virus or a virus with transmitted
Wild-type NRTI TDRMa NNRTI TDRMa PI TDRMa
3933 218 125 107
2164 (55) 135 (62) 85 (68) 66 (62)
848 (22) 48 (22) 16 (13) 17 (16)
442 (11) 12 (6) 11 (9) 12 (11)
325 (8) 16 (7) 9 (7) 8 (7)
154 (4) 7 (3) 28 (2) 4 (4)
3084 (78) 190 (87) 107 (86) 88 (82)
1852 (47) 138 (63) 79 (63) 57 (53)
1402 (36) 50 (23) 28 (22) 37 (35)
337 (9) 7 (3) 10 (8) 5 (5)
342 (9) 23 (11) 8 (6) 8 (7)
2553 (65) 183 (84) 94 (75) 78 (73)
1306 (33) 31 (14) 27 (22) 27 (25)
74 (2) 4 (2) 4 (3) 2 (2)
1099 (28) 75 (34) 49 (39) 41 (38)
130 (3) 8 (4) 6 (5) 2 (2)
2704 (69) 135 (62) 70 (56) 64 (60)
) 4.9 (4.3-5.3) 4.9 (4.3-5.5) 4.8 (4.1-5.5) 4.7 (4.3-5.2)
540) 350 (177–534) 400 (186–572) 426 (275–577) 386 (251–593)
) 35 (29–42) 35 (28–42) 35 (29–43) 34 (29–39)
se transcriptase inhibitor; PI, protease inhibitor; MSM: men who have sex with
%), 39 (31.2%), and 28 (26.2%) patients in the NRTI, NNRTI, and PI drug class,
ulti-class resistance was found for the combination NRTI-NNRTI in 38 patients,
classes was found in 16 patients.
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(48%), followed by heterosexuals (35%) and injection drug
users (8%). Most patients were male (80%). Most patients
were diagnosed with HIV in their thirties. Nearly one third
of patients were defined as recently infected (<1 year).
Subtype B was the most frequent viral subtype (66%). At
time of diagnosis the median log plasma HIV-RNA was
4.9 copies/ml (IQR: 4.3-5.3) and the median CD4 cell
count 352 cells/mm3 (IQR: 180–540). Table 2 shows the
characteristics of all included HIV-1 patients and patients
included in the years 2002 to 2005 and 2006 to 2007.
Prevalence of resistance
The overall prevalence of TDRM in newly diagnosed pa-
tients during the period 2002–2007 was 8.9% (95% CI:
8.1-9.8), of whom 69% were infected with viruses car-
rying a single TDRM. Most mutations found were asso-
ciated with nucleos(t)ide reverse transcriptase inhibitor
(NRTI) resistance at 5.0% (95% CI: 4.4-5.7), but NNRTI
resistance mutations at 2.9% (95% CI: 2.4-3.4) and pro-
tease inhibitor (PI) resistance mutations (2.5%; 95% CI:
2.1-3.0) were also observed. Dual- and multi-class resis-
tance was seen in 0.8% and 0.4% of the patients, respec-
tively. Most NRTI TDRM (184 of 218, 84.4%) were of
the thymidine analogue mutations (TAMs) class that are
associated with resistance to zidovudine and stavudine.Table 2 Characteristics of all included HIV-1 patients and pat
to 2007
Characteristics Categories
Patients
Continent of origin, no (%) Western Europe
Eastern Europe & Central Asia
Sub-Saharan Africa
Other
Unknown
Gender, no. (%) Male
Risk group, no. (%) MSM
Hetero
Injecting drug use
Unknown
Subtype, no. (%) B
non-B
Unknown
Duration of infection, no (%) <1 year
1-2 years
Unknown
Plasma HIV-RNA, median (IQR), log copies/ml
CD4 cell count, median (IQR), cells/mm3
Age, median years (IQR)The highest prevalence was found for the revertant
mutations at position 215 (S/D/C/E/I/V at 2.7%), followed
by M41L (1.7%), and L210W (0.6%). The most prevalent
drug resistant mutations were K103N (1.7%), G190A
(0.5%), Y181C (0.4%) for NNRTI and L90M (0.6%) for PI.
Factors associated with TDRM
We analyzed which factors were associated with drug re-
sistance for both the total TDRM group as well as for the
subgroups by drug class (Additional file 1: Tables S1
and S2). In a univariate analysis, several factors were asso-
ciated with the presence of overall TDRM. These factors
included a Western European origin (odds ratio [OR],
1.35, P = 0.008), CD4 cell count (square root transformed)
(OR: 0.82, P = 0.01), MSM (OR:1.80, P < 0.0001), subtype
B (OR:2.06, P < 0.0001) and recent infection (OR:1.43,
P = 0.001). In a multivariate analyses, only the MSM
(OR:1.41, P = 002) and subtype B (OR:1.49, P = 002)
remained significant. The NRTI and NNRTI drug classes
showed the same significant predictors for resistance in
the univariate analyses as was shown for the overall
TDRM, although the square root CD4 cell count was not
being associated with resistance for the NRTI drug class.
In the multivariate analyses only the MSM risk group
(OR:1.41, P = 0.03) and subtype B (OR:1.49, P = 0.001)
remained significant for the NRTI drug class. For theients included in the years 2002 to 2005 and 2006
Total 2002-2005 2006-2007
4317 2687 1630
2404 (56) 1608 (60) 796 (49)
919 (21) 424 (16) 495 (30)
472 (11) 323 (12) 149 (9)
354 (8) 190 (7) 164 (10)
168 (4) 142 (5) 26 (2)
3411 (79) 2080 (77) 1331 (82)
2084 (48) 1230 (46) 854 (52)
1501 (35) 1004 (37) 497 (30)
355 (8) 208 (8) 147 (9)
377 (9) 245 (9) 132 (8)
2855 (66) 1777 (66) 1078 (66)
1381 (32) 849 (32) 532 (33)
81 (2) 61 (2) 20 (1)
1236 (29) 724 (27) 512 (31)
144 (3) 77 (3) 67 (4)
2937 (68) 1886 (70) 1051 (64)
4.9 (4.3-5.3) 4.9 (4.3-5.3) 4.8 (4.2-5.4)
352 (180–540) 343 (163–533) 370 (210–548)
35 (29–42) 35 (29–42) 35 (29–42)
BA
p=0.36
p=0.44
p=0.004
p=0.001
p=0.44
p=0.13
p=0.16
Figure 1 Smoothed line of prevalence of TDRM in patients
diagnosed from 2002 to 2007 at time of sequence sampling.
(A) Prevalence of TDRM associated with any of the drug classes
(any class), nucleoside reverse-transcriptase inhibitor (NRTI),
nonnucleoside reverse-transcriptase inhibitor (NNRTI), and protease
inhibitor (PI). (B) Prevalence of mutations associated with nucleoside
reverse-transcriptase inhibitors (NRTI), thymidine analogue mutations
(TAM) and revertants, and the M184V mutation. The p-values of the
time trends are shown. The multivariate time trend analyses did not
change the time trend estimates and significance.
Table 3 Logistic regression of the effect of time-in-years
on the prevalence of resistance with and without
adjustment of risk-factors
Univariate Multivariate*
OR (95% CI) p-value OR (95% CI) p-value
Any 1.03 (0.97-1.1) 0.37 1.00 (0.93-1.08) 0.92
NRTI 1.03 (0.95-1.13) 0.44 1.01 (0.91-1.12) 0.84
NNRTI 1.18 (1.05-1.32) 0.004 1.15 (1.01-1.31) 0.03
PI 0.81 (0.72-0.92) 0.001 0.81 (0.71-0.92) 0.002
*In the multivariate analyses we included the factors associated with TDRM.
For Any, NRTI, and NNRTI these were Continent of origin, MSM, subtype B,
recent infection as well as CD4 count for Any and NNRTI. For the PI drug class
the factors associated with TDRM were log HIV-RNA load, age per 10 years,
square root CD4 cell count, and recent infection.
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TDRM were log HIV-RNA load, age per 10 years, square
root CD4 cell count, and recent infection. None of these
factors remained significant in the multivariate analyses.
Table 1 shows that most characteristics were similar
for patients infected with an NRTI-TDRM, an NNRTI-
TDRM, or a PI-TDRM virus. For example, similar pro-
portions originating from Western Europe were seen in
patients infected with a virus with NRTI-TDRM (62%),
NNRTI-TDRM (68%), or PI-TDRM (62%). The pro-
portion of males ranged between 82 and 87%, and the
proportion of MSM between 53 and 63% in the three re-
sistance groups. The duration of infection was similar in
all three groups. The proportion of patients recently in-
fected was 34% in the NRTI, 39% in the NNRTI and
38% in the PI TDRM groups.
TDRM trends over time
Logistic regression showed that the overall prevalence of
TDRM (8.8% in 2002 and 9.8% in 2007) was stable over
time (OR, 1.03 [95% CI, 0.97-1.10]; p = 0.37) (Figure 1A
and Table 3). Interestingly, we did observe significant
changes in resistance to particular classes of antiretroviral
drugs. For the NNRTI TDRM, the prevalence was 2.0% in
2002 and increased to 4.1% in 2007. Logistic regression
showed that this increase was significant (OR, 1.18
[95% CI, 1.06-1.32]; p = 0.004). In contrast, for PI TDRM,
the highest prevalence was found in 2002 at 3.9% and it
decreased significantly over time to 1.6% in 2007 (OR,
0.81 [95% CI, 0.72-0.92]; p = 0.001). The prevalence of
NRTI TDRM was stable, at 5.0% in 2002 and 5.2% in 2007
(OR, 1.03 [95% CI, 0.95-1.13]; p = 0.44). Factors associated
with TDRM (P < 0.1) were included in the multivariate
time trend analyses. Adjusting for these factors did not
affect the time trend estimates and significance. When
examining the incidence of TDRM over time in recently
infected patient, we observed the same increasing trend
for NNRTI (2.9% in 2002 and 3.8% in 2007) as well as the
decreasing trend for PI (5.9% in 2002 and 2.2% in 2007).
However, due to the low number of included patients in
this analyses, these trend did not remain significant (data
not shown).
We investigated several hypotheses that could explain
the increase in transmission of NNRTI TDRM. The first
possible explanation could be that a few patients infected
with a strain that contains transmitted NNRTI resistance
transmitted their virus to substantial numbers of other
individuals. However, this explanation is not plausible as
phylogenetic analyses showed several different clusters
containing the K103N amino acid substitution and these
clusters were comprised of only a small number of pa-
tients (Figure 2). Second, an increase in transmitted
NNRTI resistance could be explained by migration from
Africa, as nevirapine is frequently used for prevention of
12
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Figure 2 (See legend on next page.)
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Figure 2 The K103N mutation in phylogenetic analyses of HIV-1 subtype B pol sequences. The reliability of tree topologies was assessed
by bootstrapping with 1000 replicates. A bootstrap support of 70%, or greater, are shown at nodes on the tree. The source of the data, the
country of residence, and the presence of an NNRTI resistance mutation are included in the sequence-label. The 16 square brackets show patients
in a phylogenetic cluster with bootstrap support of >70% and a mean genetic distance of <0.03 nucleotide substitutions per site; (●) indicated
patients with a K103N mutation; (▲) highlights a reference sequence.
Frentz et al. BMC Infectious Diseases 2014, 14:407 Page 7 of 12
http://www.biomedcentral.com/1471-2334/14/407mother-to-child-transmission in Africa. From Table 1 it
can be concluded that this is unlikely given that only eight
(9%) patients with a single NNRTI mutation were coming
from Sub-Saharan Africa.
We further investigated the time trends for specific
TDRM within the NRTI drug class. TAMs were selected
in many treated patients before the HAART era by
single and dual therapy including zidovudine or stavu-
dine. The M184V mutation can be selected by the drugs
emtricitabine, lamivudine, and abacavir. Any of these
drugs have been part of the recommended NRTI back-
bones in treatment that were in use during the time that
we collected our data [17-20]. We detected the M184V
mutation in 16 patients (0.4%). Figure 1B shows that
both the prevalence of the TAMs and corresponding re-
vertants and the M184V mutations were stable over time
(OR, 1.07 [95% CI, 0.98-1.18]; p = 0.13 and 0.79 [95% CI,
0.56-1.10]; p = 0.16, respectively).
Discussion
We studied the prevalence of transmission of drug re-
sistance among patients newly diagnosed with HIV-1 in
Europe. The overall prevalence of TDRM remained stable
over time in Europe at a level that is just below 10%. But,
the underlying prevalence of TDRM associated with
particular antiretroviral drug classes showed important
changes over time. We found a significant increase in the
prevalence of transmitted NNRTI resistance, doubling
from 2.1% in 2002 to 4.1% in 2007. In contrast, trans-
mitted PI resistance decreased significantly from 3.9% to
1.6%. Transmitted NRTI resistance mutations remained
stable over time (5.7%) and generally involved TAM
mutations.
We investigated TDRM trends with data collected by
the pan-European SPREAD programme. Several studies
reported on the changes of TDRM over time in single
countries in Europe [21-26]. Recent data from Italy are in
agreement with our results. The Italian study reported a
similar significant decrease in resistance to PIs and NRTIs
and an increase in resistance to NNRTIs in the same time
frame [23]. Also, a study in seroconverters in Germany
found stable overall resistance and an increase over time
for NNRTI resistance (although not significant) between
1996 and 2007. However, transmitted NRTI resistance
was decreasing and PI resistance was stable over time
[24]. In the UK, the prevalence of TDRM was decreasing
from 2002 to 2007, followed by a slight increase in 2009.This later rise was mainly a result of increases in resistance
to NRTIs and PIs [26]. In Sweden, a low overall prevalence
of resistance was found (5.8%) and no clear trend over
time [25]. In addition, a study from Belgium found no
changes over time, which can partly be explained by the
smaller sample size in this study and thus the reduced
power to detect statistically significant changes [22].
Comparable to Europe, in North America antiretro-
viral drugs have been available for a prolonged time. A
recent published study in San Francisco reported an in-
crease of prevalence of TDRM between 2003 and 2007
whereas the prevalence decreased not-significantly after-
wards [27]. In Canada, Burchell et al. showed an increa-
sing trend of TDRM prevalence from 2002 to 2009 due
to an increase of TDRM to NRTIs and NNRTIs.
In the previous study published by the SPREAD pro-
gramme, transmitted NNRTI resistance showed a sta-
tistically significant parabolic time trend over the time
period of 2002 to 2005 (n = 2687) with a peak at the end
of 2004 (p = 0.02) [2]. The change from a parabolic to a
linear increase over time that was found in this study,
which includes the years 2006 and 2007 (n = 1630),
could be explained by the longer time period covered
and the increase in power to calculate time trends. Fur-
thermore, the data from 2006 and 2007 showed that the
initial increase in NNRTI resistance that was seen in the
previous study persisted in these later years.
We investigated several factors that could explain the
increase of transmitted NNRTI resistance in Europe. Mi-
gration from Africa could have explained the increase as
a single-dose of the NNRTI nevirapine has been used
extensively for prevention of mother-to-child-transmis-
sion, which resulted in increased levels of NNRTI resis-
tance [28]. However, this is highly unlikely because only
8 (9%) patients with a single NNRTI mutation came
from Sub-Saharan Africa in our dataset. Second, it is
important to note that virological studies showed that the
K103N, a major NNRTI mutation, can persist in the ab-
sence of treatment [29]. However, our phylogenetic ana-
lyses indicated that an increase in transmitted NNRTI
resistance did not occur within only a few large phyloge-
netic clusters thus suggesting that TDR with K103N origi-
nated from different sources. This is in agreement with
literature, where phylogenetic analyses in antiretroviral
naïve patients showed clustering of resistant sequences
[30-32]. This mostly involved NRTI mutations, whereas
large NNRTI mutations clusters have not been observed.
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increased rates of transmitted NNRTI resistance muta-
tions. NNRTIs have become more popular in first-line
treatment as international guidelines have increasingly re-
commend the use of NNRTI for initial therapy [17,18,33].
as they have good clinical efficacy [34,35] and are conve-
nient to use (low pill burden) which improves adherence
[36]. Changing initial therapy has been shown, for example
in The Netherlands [37]. Unfortunately, NNRTIs have a
low genetic barrier to drug resistance. A single amino acid
change is sufficient for high level drug resistance to the
most commonly used NNRTIs in first-line treatment [38].
We believe that with the use of NNRTIs in first line regi-
mens (in combination with emtricitabine/lamivudine plus
either tenofovir or abacavir) resistant viruses can become
selected in failing patients. Early after failure these viruses
carry a single NNRTI mutation often combined with the
M184V/I [39]. M184V has a strong effect on replication
capacity and if transmitted, reverts back to wild-type ra-
pidly (68% after 6 months of HIV infection [40]). In con-
trast, the K103N has a limited effect on viral replication
capacity and persist for long periods after transmission
and strains with this mutation are therefore also transmit-
ted to others (onward transmission) [41].
The decreasing transmission of PI resistant mutations
can also be explained by changes in prescribing practices
over time. From 2004, the guidelines for treatment of
adult HIV infection have recommended the use of
NNRTIs over PIs due to better virological outcome, lower
rates of toxic effects, and fewer interactions between drugs
[18]. In addition, over time PIs have increasingly been
given with low dose ritonavir (or boosted PIs), which have
a high genetic barrier for drug resistance. Therefore
the chance of selecting resistant viruses upon treatment
failure is very low [42-44], likely resulting in a decreased
rate of PI versus NNRTI- TDR.
The persistent high levels of TAMs and revertants over
the years are not in line with prescribing practices. TAMs
were originally selected by the thymidine analogues stavu-
dine and zidovudine, which have been used extensively in
the past but have over time become less common in first-
line treatment [45,46]. The persistently high levels of
TAMs and revertants can be explained by initial selection
in the early 1990s, and subsequently the original selected
mutations may have persisted. In addition, revertants or
intermediates have evolved in the absence of drug pres-
sure and persisted since then. This is confirmed by several
studies showing that TAMs and revertants tend to persist
in the absence of antiretroviral drugs [29,40]. Given that
we find transmitted TAMs also in patients with recent in-
fection despite the decreasing use of zidovudine during
the study period indicates that these viruses are descen-
dants of resistant viruses generated ten to fifteen years ago
that still are circulated and being transmitted.A limitation of our study is that we used population se-
quencing to identify drug resistance associated mutations.
Although population sequencing is standard practice
across Europe, this technique fails to identify drug-resist-
ant minority variants that are present in <20% of the virus
population infecting a patient [47]. These minority va-
riants have been detected in almost 20% of antiretroviral
naïve HIV-infected individuals [48]. The presence of
minorities, particularly involving NNRTI resistance, is as-
sociated with an increased risk of virological failure to
first-line therapy [48]. The increasing levels of transmitted
NNRTI resistance are therefore worrying, as we most
probably underestimate the real prevalence in this study.
Representativeness of the data could also be a limitation
in our study. We assessed the representativeness by com-
paring the distribution of the transmission groups in all
countries included in SPREAD with the HIV surveillance
data from the European Centre for Disease prevention
and Control (ECDC) (data not shown). The proportional
distribution of the different transmission groups was very
comparable. However, compared to the data from ECDC,
MSM were somewhat over-represented in some of the
countries participating in SPREAD. This may suggest that
the estimated prevalence in our study might be slightly
overestimated.
A strength of our study is the data collection that
is performed within the SPREAD programme. The
SPREAD programme is a large and sufficiently powered
pan- European study that has been running since almost
ten years. During this time the programme included
patients newly diagnosed with HIV using a predefined
strategy that is based on the transmission routes and
geographical distribution of HIV in the participating
countries.
The SPREAD programme studies the prevalence of
TDRM in newly diagnosed patients, of which most pa-
tients are chronically infected. Several studies showed that
resistance levels in recently infected patients are higher
compared to those in chronically infected patients [24,49].
The reason for choosing to investigate newly diagnosed
patients is that these patients reflect the patients coming
under medical attention. Furthermore, to limit the ana-
lyses only to recently infected patients might give a biased
result, as MSM (which have higher prevalence of TDRM)
are being tested more frequently and are therefore more
often recently infected at HIV-diagnosis compared to
other risk-groups.
The results from this study have several implications
for clinical practice and public health. The single TAMs
and revertants found do generally not cause resistance
to nucleos(t)ides currently popular in first-line regimens
(emtricitabine, tenofovir, lamuvidine, abacavir). There-
fore, the high prevalence of resistance to single TAMs
that was found in Europe probably will not have a great
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prevalence of PI mutations and their negligible effect on
the efficacy of boosted PIs also implies that they will not
have a major public health implication. Conversely, the
increasing prevalence of transmitted NNRTI resistance
is likely to negatively influence the therapy response
to NNRTI-containing regimens. Since it is it unknown
whether the increasing NNRTI resistance levels will in-
crease even more or will level-off, surveillance of TDRM
will remain important.
Conclusions
In conclusion, during the last decade, rates of transmit-
ted resistance to certain drug classes have changed con-
siderably. PI resistance declined between 2002 and 2007.
In contrast, a significant increase in transmitted NNRTI
resistance was observed. This finding underscores the
importance of baseline drug-resistance testing prior to
the beginning of treatment, given the medical evidence
that transmitted NNRTI reduces the efficacy of current
first line NNRTI-based regimens [8].
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